GoodRx Holdings Receives Analyst Ratings

Summary

GoodRx Holdings, Inc. (NASDAQ: GDRX) received a ‘moderate buy’ consensus rating from eleven analysts, consisting of five hold ratings, five buy ratings, and one strong buy rating. The average one-year price target is $6.55. Recently, some brokerages lowered their price targets, with Goldman Sachs rating it as neutral with a $5.00 target price. The company’s last quarterly earnings report showed an EPS of $0.09, surpassing expectations, with revenue of $202.97 million. The stock opened at $4.87 with a market cap of $1.74 billion and a P/E ratio of 60.88. Institutional investors own 63.77% of the shares.Market Beat GoodRx will release its Q2 2025 financial results on August 6, 2025.Reuters

Impact Analysis

The event is at the company level, specifically impacting GoodRx Holdings. The consensus ‘moderate buy’ rating and recent price target adjustments suggest mixed sentiment among analysts, indicating potential volatility or uncertainty about the company’s near-term performance. The company’s past earnings exceeded expectations, which may provide a positive basis for future performance. However, the recent target price reductions by brokerages like Goldman Sachs and Truist Financial highlight possible concerns over future growth or market conditions. With institutional investors holding a significant share, their actions could significantly impact the stock’s movement. The upcoming Q2 financial results on August 6, 2025, will be critical for investors to reassess the company’s financial health and growth prospects, potentially affecting stock price movements directly following the announcement.Market Beat+ 2